Skip to content

Finding the Latent Treponema Pallidum

Finding the Latent Treponema Pallidum of Syphilis With Serofast Status

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03754517
Enrollment
30
Registered
2018-11-27
Start date
2016-08-31
Completion date
2019-12-31
Last updated
2019-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Keywords

syphilis, serofast

Brief summary

Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, srum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

Detailed description

Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, serum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

Interventions

DIAGNOSTIC_TESTRPR Titer

RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* All clinical diagnosis of syphilis cases

Exclusion criteria

* Auto-immune disease (such as SLE) * Lyme disease

Design outcomes

Primary

MeasureTime frameDescription
the reads of treponema pallidum30 daysUsing the Next-Generation Sequencing to test specific genome of treponema pallidum for syphilis

Countries

China

Contacts

Primary ContactJun Li
lijun35@hotmail.com01069151502

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026